Business Wire

Australia Flexes Muscle in Talent War with Newest Immigration Program

Share

The global battle for talent supercharged by the Covid-19 pandemic shows no signs of abating, with Australia sending out strong signals that it intends to succeed with its latest immigration offering under the Australia Global Business and Talent Attraction Taskforce. Under the purview of the taskforce, there is a fast-tracked visa program with a streamlined path to permanent residence for talented individuals. The Global Talent visa has been designed to grow Australia’s innovation and tech economies in a bid to boost economic recovery, enhance resilience, and drive competitiveness by attracting dynamic, highly skilled individuals to relocate to its safe shores.

With no age limit or investment prerequisite, the only requirements for applicants are to be internationally recognized, prominent in their field, and able to provide evidence of outstanding achievements. The 10 future-focused target sectors are: Agri-food and AgTech, Energy, Health Industries, Defence, Advanced Manufacturing and Space, Circular Economy, DigiTech, Infrastructure and Tourism, Financial Services and FinTech, and Education. Places are also available to internationally recognized master’s and PhD students demonstrating exceptional talent.

Peter Verwer, the Prime Minister’s Special Envoy for Global Business and Talent Attraction, says, “Australia has managed the Covid-19 crisis extremely well, but its economy, like many others around the world, has taken a hit. This is precisely why Australia established the Global Business and Talent Attraction Taskforce. It serves to attract high-value businesses and exceptionally talented individuals such as top scientists, tech entrepreneurs, and investors, along with their ideas, networks, and capital, to work and live permanently in Australia. This will in turn create opportunities for Australians by transferring skills, promoting innovation, and creating jobs.”

Director of leading international citizenship and residence advisory firm Henley & Partners’ Australia office, Tony Le Nevez, says that along with its focus on the future, the country’s prosperity, safety, and exceptional quality of life make it a highly sought-after destination. “Stimulating innovation — tech innovation in particular — is non-negotiable for any sovereign state in the current context. By attracting and harnessing the world’s cutting-edge talent, Australia’s Global Talent visa offering will ensure that the country stays well ahead of the game. The pandemic has evoked a strong desire for change, leading many individuals to seek out alternatives. Australia was one of the top-performing countries in the Investment Migration Programs Health Risk Assessment, and the Global Talent visa presents a perfect opportunity for matching the best talent with a safe, reliable, and successful country that is forward looking.”

India is among the top countries showing interest in the Global Talent visa program along with the UK and the US, according to statistics from the Australian Department of Home Affairs. Successful applicants are able to obtain fast-tracked permanent residence for the whole family within six weeks, which makes the program extremely appealing. For those keen on learning more about the Global Talent visa, Henley & Partnerswill be hosting an exclusive panel discussion with Verwer and Le Nevez on Wednesday, 28 April 2021 at 12:00 noon IST (14:30 SGT). For more details, see here.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact
Alina Morais
Head of PR, Southeast Asia
alina.morais@henleyglobal.com
+65 9295 4792

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye